Literature DB >> 12075858

Increased neopterin production and tryptophan degradation in advanced Parkinson's disease.

B Widner1, F Leblhuber, D Fuchs.   

Abstract

Large amounts of neopterin are produced by interferon-(IFN)-gamma-stimulated human monocytes/macrophages, and increased neopterin concentrations indicate cellular immune activation. In parallel, IFN-gamma induces indoleamine 2,3-dioxygenase which degrades 1-tryptophan to kynurenine. Increased tryptophan degradation rates are indicated by an increased kynurenine/tryptophan ratio (kyn/trp-ratio), reflecting immune system activation, too. In 22 patients with Parkinson's disease (PD) and in 11 age-matched controls, serum and cerebrospinal fluid (CSF) neopterin concentrations were measured by ELISA. Tryptophan and kynurenine concentrations were determined by HPLC. Neopterin concentrations and kyn/trp-ratios were increased both in serum and CSF of patients as compared to controls. Serum tryptophan was lower in patients. Patients with the highest disease activity presented with highest degree of immune activation. Significant correlations existed between neopterin concentrations and kyn/trp-ratios in serum and CSF. Increased formation of neopterin and enhanced degradation of tryptophan suggest activated cell-mediated immune response in a subgroup of patients with advanced Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12075858     DOI: 10.1007/s007020200014

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  43 in total

1.  Urinary kynurenine as a biomarker for Parkinson's disease.

Authors:  Jia-He Bai; Ya-Li Zheng; Yong-Peng Yu
Journal:  Neurol Sci       Date:  2020-07-13       Impact factor: 3.307

Review 2.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Authors:  Luis Rajman; Karolina Chwalek; David A Sinclair
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

3.  A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study.

Authors:  Jacopo Troisi; Annamaria Landolfi; Carmine Vitale; Katia Longo; Autilia Cozzolino; Massimo Squillante; Maria Cristina Savanelli; Paolo Barone; Marianna Amboni
Journal:  Metabolomics       Date:  2019-06-10       Impact factor: 4.290

4.  Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.

Authors:  Gregory Oxenkrug; Marieke van der Hart; Julien Roeser; Paul Summergrad
Journal:  Endocrinol Diabetes Metab J       Date:  2017-11-19

Review 5.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

6.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

7.  Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures.

Authors:  Xin Fu; Samantha M Zunich; Jason C O'Connor; Annemieke Kavelaars; Robert Dantzer; Keith W Kelley
Journal:  J Neuroinflammation       Date:  2010-08-02       Impact factor: 8.322

8.  The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.

Authors:  Yiquan Chen; Roger Stankovic; Karen M Cullen; Vincent Meininger; Brett Garner; Sarah Coggan; Ross Grant; Bruce J Brew; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2009-11-18       Impact factor: 3.911

Review 9.  The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors.

Authors:  Zsófia Majláth; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2013-12-18       Impact factor: 3.575

Review 10.  Glial biomarkers in human central nervous system disease.

Authors:  Gwenn A Garden; Brian M Campbell
Journal:  Glia       Date:  2016-05-26       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.